Legend Biotech Corporation provided earnings guidance for the six months ended June 30, 2020. For the period, the company expects to record a loss from approximately USD 89.0 million to USD 103.0 million from continuous operations (before one-time charges, including commission fee for issuance of Series A convertible redeemable preferred shares (“Series A Preferred Shares”), changes of fair value of such Series A Preferred Shares, and listing expenses).